Sector Chart Formycon AG

Equities

FYB

DE000A1EWVY8

Biotechnology & Medical Research

Real-time Estimate Tradegate Other stock markets 15:10:19 23/01/2026 GMT			5-day change	1st Jan Change
23.88 ^EUR	-0.52%		+0.83%	-5.27%

12-23	Formycon Obtains US FDA Approval for Interchangeable Lucentis Biosimilar	MT
12-23	Formycon AG - FDA approves biologics license application (BLA) for additional ranibizumab biosimilar under trade name Nufymco	RE

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes

Sector Other Biotechnology & Medical Research

	Capi.	Sales growth	Profitability	Finances	EV / Sales	P/E
FORMYCON AG	498M					-
LONZA GROUP AG	49.33B
SEAGEN INC.	43.15B	-	-	-	-	-
IQVIA HOLDINGS INC.	40.71B
BEONE MEDICINES AG	37.49B
CELLTRION, INC.	31.07B